Figure 1.
Genome-wide CRISPR/Cas9 screens identify erdafitinib SL gene. A, Schematic showing CRISPR/Cas9 screening strategy. MOI, multiplicity of infection. B, Volcano plots showing results of genome-wide CRISPR/Cas9 negative screen. C, Shared and unique SL genes were identified (P < 0.05, log2-fold change < −0.5 and good sgRNA ≥5) in negative screen analysis. D, qRT-PCR assay showed the relative levels of SRM in human bladder cancer tissues compared with their adjacent normal tissues (n = 108). E, Kaplan–Meier curves of overall survival in patients with bladder cancer (n = 108) with low versus high expression of SRM. Patients were grouped by the median SRM expression (P = 0.0018, log-rank test). Data are presented as the means ± SD from three independent experiments. ****, P < 0.0001 (Student t test).